News
Novo Nordisk Faces $70B Blow as New CEO Steps In Amidst Weight-Loss Drug Turmoil
Novo Nordisk's market value fell by $70 billion following a profit warning and the appointment of Maziar Mike Doustdar as the new CEO. The company faces increased competition in the obesity drug market and challenges from compounded versions of its weight-loss drugs,
Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...
July 29 - Novo Nordisk (NOVO?B) shares plunged about 20% Tuesday after the Danish drugmaker warned of weaker-than?expected ...
FRANKFURT: European stocks closed higher on Tuesday, buoyed by financials and defence stocks, though Danish stocks logged ...
storage.googleapis.com on MSN7hOpinion
Novo Nordisk (NVO) Just Lost $100B and Blamed HIMSNovo Nordisk ($NVO) lost nearly $100 billion in market cap in one session and pointed fingers at Hims & Hers Health ($HIMS) ...
Here are some of the stories Wall Street is watching on Tuesday, July 29. Warren Buffett's Berkshire Hathaway (BRK-B, BRK-A) ...
European stocks closed higher on Tuesday, buoyed by financials and defence stocks, though Danish stocks logged their biggest ...
A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback